Vismodegib is not currently approved for use in pediatric cancer [1]. The drug has been studied in some pediatric patients with specific conditions, such as nevoid basal cell carcinoma syndrome (Gorlin syndrome), but it is not a standard treatment for childhood cancers [2][3].
What is Vismodegib approved for?
Vismodegib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred after surgery or who are not candidates for surgery [1].
Has Vismodegib been studied in children?
While not approved for pediatric use, Vismodegib has been investigated in clinical trials involving children. For example, studies have explored its efficacy in children with nevoid basal cell carcinoma syndrome (Gorlin syndrome), a genetic disorder that can lead to multiple basal cell carcinomas [2][3]. Research is ongoing to understand its potential role in specific pediatric conditions, but it remains an investigational therapy in this population [2].
What is the mechanism of action of Vismodegib?
Vismodegib is a hedgehog signaling pathway inhibitor [1]. The hedgehog pathway plays a role in embryonic development and can be reactivated in certain cancers, promoting tumor growth [1]. By inhibiting this pathway, Vismodegib aims to slow or stop the growth of cancer cells [1].
What are the potential side effects of Vismodegib?
Common side effects reported in adult patients treated with Vismodegib include muscle spasms, hair loss, taste changes, weight loss, fatigue, nausea, diarrhea, and decreased appetite [1]. Side effects in children may differ, and ongoing research is monitoring these in pediatric studies [2].
When does Vismodegib's patent expire?
Information regarding specific patent expiry dates for Vismodegib can be found on specialized pharmaceutical patent tracking websites [4]. These resources detail patent protections that influence market exclusivity and the potential for generic or biosimilar competition [4].